NIAID Research on HPV
In June 2006, Food and Drug Administration approved Gardasil, the first vaccine developed to prevent cervical cancer, precancerous lesions, and genital warts due to HPV types 6,11,16, and 18. FDA licensed the vaccine for use in girls and women aged 9 to 26 years.
Researchers continue to work on another vaccine for HPV to help protect against HPV types 16 and 18.